EVG.L Regulatory News (EVG)

RNS REACH

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

Upcoming Investor Presentations

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce that Dr Stephen Franklin, the Company's CEO, will present at a series of upcoming investor evenings.

The presentation will focus on the Phase II trials of SFX-01, the Company's lead product, in the treatment of breast cancer and subarachnoid haemorrhage, a type of stroke.

Investors and shareholders wishing to register for the investor presentations may do so through the links provided below.

16 May 2018 - ShareSoc Growth Company Seminar, London

Time: The presentation will start at 5.30pm followed by a buffet and refreshments.

Location: Link Asset Services, 65 Gresham Street, London, EC2V 7NQ.

Link to register: https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-london-16-may-2018/

17 May 2018 - Proactive Investors Healthcare, London

Time: The presentation will start at 6.00pm followed by drinks and canapés.

Location: Chesterfield Mayfair Hotel, 35 Charles Street, London, W1J 5EB. 

Link to register: http://www.proactiveinvestors.co.uk/register/event_details/142

19 June 2018 - ShareSoc Growth Company Seminar, Manchester

Time: The presentation will start at 5.30pm followed by a buffet and refreshments.

Location: Kuits Solicitors, 7th Floor, Blackfriars House, Manchester, M3 2JA.

Link to register: https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-19-june-2018/

A copy of the latest investor presentation will be available from 12pm on 15 May 2018 at: http://evgen.com/investors/shareholder-information/

Enquiries:

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company focussed on the development of a new class of pharmaceutical; sulforaphane-based compounds for application in oncology and neurology markets. Lead product, SFX-01, is in two Phase II trials, utilising two separate mechanistic targets, with expected read-outs around the end of 2018.

Evgen Pharma commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com

For commissioned research on the Company, please visit: http://evgen.com/investors/analyst-coverage/